Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

Literature DB >> 17242141

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

Boris V Nikonenko¹, Marina Protopopova, Rowena Samala, Leo Einck, Carol A Nacy.

Abstract

Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17242141 PMCID： PMC1855523 DOI： 10.1128/AAC.01326-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

16 in total

1. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action.

Authors: Helena I M Boshoff; Timothy G Myers; Brent R Copp; Michael R McNeil; Michael A Wilson; Clifton E Barry
Journal: J Biol Chem Date: 2004-07-09 Impact factor: 5.157

2. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.

Authors: Elena Bogatcheva; Colleen Hanrahan; Boris Nikonenko; Rowena Samala; Ping Chen; Jacqueline Gearhart; Francis Barbosa; Leo Einck; Carol A Nacy; Marina Protopopova
Journal: J Med Chem Date: 2006-06-01 Impact factor: 7.446

3. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors: B P Kelly; S K Furney; M T Jessen; I M Orme
Journal: Antimicrob Agents Chemother Date: 1996-12 Impact factor: 5.191

4. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates.

Authors: Richard E Lee; Marina Protopopova; Emma Crooks; Richard A Slayden; Marianne Terrot; Clifton E Barry
Journal: J Comb Chem Date: 2003 Mar-Apr

Review 10. Terpenyl-purines from the sea.

Authors: Marina Gordaliza
Journal: Mar Drugs Date: 2009-12-23 Impact factor: 5.118

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

1. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action.

2. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.

3. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

4. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates.

5. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

6. Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.

7. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

8. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.

9. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.

10. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Review 1. The chemical biology of new drugs in the development for tuberculosis.

Review 2. New antituberculous drugs in development.

3. Recent advances in tuberculosis: New drugs and treatment regimens.

Review 4. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Review 5. Tuberculosis pharmacotherapy: strategies to optimize patient care.

Review 6. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

7. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

Review 8. Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Review 9. The present state of the tuberculosis drug development pipeline.

Review 10. Terpenyl-purines from the sea.